

FINAL PROGRAMME



21st Annual Conference of the British HIV Association (BHIVA)

21–24 April 2015

The Brighton Centre, Brighton, UK



www.bhiva.org

#BHIVA2015

18 CPD Credits
Unique Reference No:
93270

defy

CONVENTION

Introducing a reason to rethink first-line treatment in HIV.

- Rapid and sustained efficacy through to 144 weeks¹⁻⁷
- High barrier to resistance to date¹⁻⁷
- Generally well tolerated with few discontinuations¹⁻⁷
- Once daily with few DDIs or dosing restrictions⁸

*TIVICAY is dosed 50 mg once daily for patients without documented or clinically suspected resistance to the integrase class. TIVICAY should be dosed 50 mg twice daily in patients with resistance to the integrase class (documented or clinically suspected) or in patients taking certain concomitant medicines (e.g. efavirenz, nevirapine, tipranavir/r, or rifampicin).⁸

Tivicay[®] ▼ dolutegravir 50mg tablets Prescribing Information

See Summary of Product Characteristics before prescribing

Indication: HIV in >12 years and ≥40kg as part of combination therapy. **Dosing:** 50mg once daily with or without food if no proven/ suspected integrase resistance. 50mg twice daily with efavirenz, nevirapine, tipranavir/ritonavir or rifampicin. *Adults with proven/ suspected integrase resistance:* 50mg twice daily preferably with food. *Elderly:* Limited data in 65+ yrs. Caution in severe hepatic impairment. **Contraindications:** Hypersensitivity to any ingredient. Co-administration with dofetilide. **Warnings/ precautions:** Risk of hypersensitivity reactions. Discontinue dolutegravir and other suspect agents immediately if suspected. Risks of osteonecrosis, immune reactivation syndrome. Monitor LFTs in Hepatitis B/C co-infection and ensure effective Hepatitis B therapy. Monitor with metformin. Use with etravirine requires boosted PI. Use with Mg/ Al-containing antacids, calcium, multivitamins or iron requires dosage separation. Use with St John's Wort and some anti-epileptic drugs not recommended. **Pregnancy/ lactation:** Not recommended. Avoid breast-feeding. **Side effects:** See SPC for full details. Headache, GI disturbance, insomnia, abnormal dreams, dizziness, rash, pruritus, fatigue, elevations of ALT, AST and CPK, hypersensitivity. **Basic NHS costs:** 30 tablets £498.75 EU/1/13/892/001. MA holder: ViiV Healthcare UK Ltd, 980 Great West

Road, Brentford, Middlesex TW8 9GS. Further information available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT.

POM

Tivicay is a registered trademark of the ViiV Healthcare Group of Companies

Date of approval: November 2014

Zinc code: UK/DLG/0055/13(5)

Adverse events should be reported. For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

Adverse events should be reported. For Ireland, adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971, medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Reference

1. Walmsley S et al. N Engl J Med. 2013;369(19):1807-1818. 2. Walmsley S et al. Poster presented at: 21st Conference on Retroviruses and Opportunistic Infections; March 3-6, 2014; Boston, Massachusetts, USA. Poster 543. 3. Pappa K et al. Abstract presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 5-9, 2014; Washington, DC, USA. 4. Clotet B et al. Lancet. 2014;383:2222-2231. 5. Molina J-M et al. J Int AIDS Soc. 2014;17(suppl 3):19490. 6. Raffi F et al. Lancet Infect Dis. 2013;13(11):927-935. 7. Raffi F et al. Lancet. 2013;381(9868):735-743. 8. TIVICAY (dolutegravir) Summary of Product Characteristics 09/2014

UK/DLG/0068/13(2) Date of preparation: January 2015

ViiV Healthcare TIVICAY is a trademark of the ViiV Healthcare group of companies.
©ViiV Healthcare group of companies 2015. All rights reserved.

Tivicay[®] ▼
dolutegravir

CONTENTS AND LOCATIONS

BHIVA Committees	4
Programme Summary	5
Programme	6–14
Satellite Symposia and Workshops	16,17
Exhibition Floor Plan and Exhibitors	18
Conference Information	19,20
Conference Scholarships and Awards	21
Social Events	22
BHIVA Plenary Speakers, Biographies	24–26
Sponsors and Exhibitors	27

Badges must be worn at all times in order to gain access to the lecture theatre, exhibition and dining areas

VENUES AND LOCATIONS

All locations are in the Brighton Centre, unless stated otherwise

Registration	Foyer, Ground Floor
Lecture Theatre	Auditorium 1, First Floor
Exhibition	Foyer, Ground Floor
Posters	Meeting Room 1, Ground Floor
Lunch and Refreshments	Foyer, Ground Floor
BHIVA Lunchtime Workshops, 1, 3, 5	Syndicate Room 1
BHIVA Lunchtime Workshops, 2, 4, 6	Syndicate Room 2
Satellite Symposia	Auditorium 1, First Floor
Sponsors' Workshops	Syndicate Rooms 3 and 4
Speakers' Preview Room	2Bar, First Floor
Sponsors' Rehearsal Room	Meeting Room 8
Welcome Reception	Auditorium 1, First Floor Reception: Foyer, Ground Floor
Gala Dinner	The Grand Brighton Hotel

18 CPD Credits

Unique reference number: 93270

BHIVA COMMITTEES

BHIVA EXECUTIVE COMMITTEE

OFFICERS

Chair

Dr D Asboe Chelsea and Westminster Hospital, London

Vice Chair

Dr AJ Palfreeman Leicester Royal Infirmary

Honorary Secretary

Dr A de Ruiter St Thomas' Hospital, London

Honorary Treasurer

Dr D Churchill Royal Sussex County Hospital, Brighton

MEMBERS

Prof B Angus University of Oxford

Prof M Bower Chelsea and Westminster Hospital, London

Mr G Brough UK Community Advisory Board

Dr D Chadwick James Cook University Hospital, Middlesbrough

Dr M Chaponda Royal Liverpool University Hospital

Dr L Dorrell University of Oxford

Prof MJ Fisher Brighton and Sussex Medical School

Dr AR Freedman Cardiff University School of Medicine

Prof BG Gazzard Chelsea and Westminster Hospital, London

Professor C Leen Western General Hospital, Edinburgh

Ms S Morris Western General Hospital, Edinburgh

Dr C Orkin Barts Health NHS Trust, London

Prof C Sabin University College London

Dr A Sullivan Chelsea and Westminster Hospital, London

Dr M Tenant-Flowers King's College Hospital NHS Foundation Trust, London

Dr L Waters Mortimer Market Centre, London

CONFERENCES SUBCOMMITTEE

Dr C Orkin Chair

Dr L Waters Vice Chair and BHIVA Executive Committee member

Dr D Asboe BHIVA Executive Committee member

Mr G Brough BHIVA Executive Committee member and Community Representative

Dr D Churchill BHIVA Honorary Treasurer and Local Host

Dr M Chaponda BHIVA Executive Committee member

Dr A de Ruiter BHIVA Executive Committee member

Dr C Emerson Invited Representative

Prof M J Fisher BHIVA Executive Committee member

Prof B Gazzard Chelsea and Westminster Hospital, London

Prof C Leen BHIVA Executive Committee member

Ms S Morris BHIVA Executive Committee member

Dr M Nelson Invited Representative

Dr A Palfreeman BHIVA Executive Committee member

Prof C Sabin Education and Scientific Subcommittee Chair

Dr M Tenant-Flowers BHIVA Executive Committee member

Dr E Wilkins Invited Representative

ORAL RESEARCH JUDGING PANEL

Laura Waters (Chair) Mortimer Market Centre, London

Tristan Barber Chelsea and Westminster Hospital, London

Mas Chaponda Royal Liverpool University Hospital

Gillian Dean Royal Sussex County Hospital, Brighton

Martin Fisher Brighton and Sussex Medical School

Alastair Hudson The People Living with HIV Stigma Index

Caroline Sabin University College London

Melinda Tenant-Flowers King's College Hospital NHS Foundation Trust, London

POSTER PRESENTATION JUDGING PANEL

Adrian Palfreeman (Chair) Leicester Royal Infirmary

Garry Brough UK Community Advisory Board

Amanda Clarke Royal Sussex County Hospital, Brighton

Carol Emerson The Royal Hospitals, Belfast

Sarah Fidler Imperial College Healthcare NHS Trust, London

Yvonne Gilleece Royal Sussex County Hospital, Brighton

Chloe Orkin Barts Health NHS Trust, London

Emma Rutland St Richard's Hospital, West Sussex

PROGRAMME SUMMARY

TUESDAY 21 APRIL 2015

1700–2000	Registration open at the Brighton Centre
1730–2000	BHIVA New Consultants Forum

WEDNESDAY 22 APRIL 2015

0800–1900	Registration and Exhibition open at the Brighton Centre
0850–0900	Welcome Address
0900–1000	BHIVA Invited Lecture 1 and 2
1000–1100	Gilead Sciences Satellite Symposium
1100–1120	Morning coffee
1120–1220	Janssen Satellite Symposium
1220–1300	BHIVA Review Session
1300–1500	Lunch, Workshops and Poster Presentations
1310–1355	BHIVA Lunchtime Workshops 1 and 2
1355–1455	Gilead Sciences Lunchtime Workshops
1355–1455	Janssen Lunchtime Workshops
1500–1530	MRC Clinical Trials Unit Session
1530–1630	Oral Research Presentations: Session 1
1630–1700	Afternoon tea
1700–1800	BHIVA Plenary Session 1
1800–1900	ViiV Healthcare Satellite Symposium
1900–2000	Welcome Reception

THURSDAY 23 APRIL 2015

0800–1830	Registration and Exhibition open at the Brighton Centre
0900–1000	MSD Ltd Satellite Symposium
1000–1100	BHIVA Plenary Session 2
1100–1130	Morning coffee
1130–1300	Oral Research Presentations: Session 2
1300–1500	Lunch, Workshops and Poster Presentations
1310–1355	BHIVA Lunchtime Workshops 3 and 4
1355–1455	Bristol-Myers Squibb Pharmaceuticals Lunchtime Workshop
1355–1455	ViiV Healthcare Lunchtime Workshops
1500–1630	Oral Research Presentations: Sessions 3
1630–1700	Afternoon tea
1700–1730	BHIVA Audit Session
1730–1830	BHIVA Plenary Session 3
1945–0030	Gala Dinner: The Grand Brighton Hotel

FRIDAY 24 APRIL 2015

0800–1430	Registration and Exhibition open at the Brighton Centre
0900–1000	BHIVA Invited Lectures 3 and 4
1000–1030	BHIVA Keynote Lecture
1030–1100	Morning coffee
1100–1200	Oral Research Presentations: Session 4
1200–1230	Oral Poster Presentations
1230–1430	Lunch, Workshops and Poster Presentations
1240–1325	BHIVA Lunchtime Workshops 5 and 6
1325–1425	Sponsors' Lunchtime Workshops
1430–1445	BHIVA Prizes and Awards Ceremony
1445–1515	BHIVA Invited lecture 5
1515–1615	BHIVA Plenary Session 4
1615	Close

PROGRAMME

TUESDAY 21 APRIL 2015

1700–2000

Registration open at The Brighton Centre

1730–2000

BHIVA New Consultants Forum, Meeting Room 3**Welcome**

Chair Dr Mas Chaponda

Royal Liverpool University Hospital

1730–1805

Job plan: negotiating the path

Ms Claire Ashley

British Medical Association

1805–1840

Business plan: how to write a good one

Dr Gabriel Schembri

Manchester Centre for Sexual Health

1840–1915

Research plan: where to get help

Professor Caroline Sabin

University College London

1915–1950

Work/life balance: get it right or else

Dr Colm O'Mahony

Countess of Chester Hospital NHS Trust

1950–2000

Summary and close

2015

New Consultants Forum Dinner

WEDNESDAY 22 APRIL 2015

0800–1900

Registration and exhibition open at The Brighton Centre

◀ All sessions will be held in Auditorium 1 unless otherwise stated ▶

0850–0900

Welcome Address by the Chair of the British HIV Association

Dr David Asboe

Chelsea and Westminster Hospital, London

0900–0930

BHIVA Invited Lecture 1

Chair: Dr Sanjay Bhagani

*Royal Free Hospital, London***Generics: the facts**

Dr Andrew Hill

University of Liverpool

0930–1000

BHIVA Invited Lecture 2

Chair: Dr Lucy Dorrell

*University of Oxford***Five general medicine facts**

Dr Laura Waters

Mortimer Market Centre, London

1000–1100

Gilead Sciences Satellite Symposium (please see page 16 for further details)

1100–1120

Morning Coffee

1120–1220

Janssen Satellite Symposium (please see page 16 for further details)

PROGRAMME

WEDNESDAY 22 APRIL 2015

1220–1300

BHIVA Review Session

Chair: Dr Chloe Orkin

Barts Health NHS Trust, London

Translating recent research into clinical practice

Dr Julie Fox

St Thomas' Hospital, London

1300–1500

Lunch, Workshops and Poster Presentations

1310–1355

BHIVA Lunchtime Workshop 1 Syndicate Room 1

Clinico-Pathological Case Presentations

Chair: Professor Sebastian Lucas

King's College London

Something old or something new?

Dr Ruairidh Buchanan

Royal Free Hospital, London

Is diarrhoea always due to protease inhibitors?

Dr Sian Warren

Cardiff Royal Infirmary

An unusual diagnostic tool

Dr Stuart Flanagan

Barts Health NHS Trust, London

1310–1355

BHIVA Lunchtime Workshop 2 Syndicate Room 2

Psychological issues in people living with HIV

Dr Stuart Gibson

Barts Health NHS Trust, London

Dr Alexander Margetts

Central and North West London NHS Foundation Trust

1355–1455

Gilead Sciences Lunchtime Workshop Syndicate Room 3 (please see page 16 for further details)

1355–1455

Janssen Lunchtime Workshop Syndicate Room 4 (please see page 17 for further details)

1500–1530

MRC Clinical Trials Unit Session

Chair: Dr Adrian Palfreeman

Leicester Royal Infirmary

PROUD and self-testing: research for policy

Professor Sheena McCormack

MRC Clinical Trials Unit at UCL, London

1530–1630

Oral Research Presentations: Session 1

HIV Testing and Service Delivery

Chairs: Dr Duncan Churchill

Royal Sussex County Hospital, Brighton

Dr Sheila Morris

Western General Hospital, Edinburgh

1530–1540 Abstract O1

The effectiveness of indicator disease-based HIV testing across Europe – results from a prospective multi-centre study

Dr Michael Rayment, Chelsea & Westminster Hospital, London

PROGRAMME

WEDNESDAY 22 APRIL 2015

1540–1550 Abstract O2

Investigating associations between a new measure of engagement in-care and clinical outcomes in the UK Collaborative HIV Cohort (UK CHIC) study

Professor Caroline Sabin, University College London

1550–1600 Abstract O3

Non-disclosure of HIV serostatus and associations with psychological factors, ART non-adherence, and viral load non-suppression among people living with HIV in the UK

Miss Marina Daskalopoulou, University College London

1600–1610 Abstract O4

Patient information leaflets (PILs) currently require graduate-level reading skills equivalent to The Guardian or The Telegraph

Mr Simon Collins, HIV i-Base

1610–1620 Abstract O5

Patient experience within NHS HIV specialist services: Results from the Positive Voices pilot survey

Ms Meaghan Kall, Public Health England

1620–1630 Abstract O6

Healthcare utilisation and non-antiretroviral medication use in people living with HIV over and under 50 years of age compared to matched controls: the Pharmacokinetics and Clinical Observations in People over Fifty (POPPY) Study

Dr Alan Winston, Imperial College London

1630–1700

Afternoon Tea

1700–1800

BHIVA Plenary Session 1: HIV transmission and prevention

Chairs: Mr Garry Brough

Terrence Higgins Trust

Professor Martin Fisher

Brighton and Sussex Medical School

MSM in the UK: prevention effects of ART in perspective

Professor Andrew Phillips

University College London

HIV transmission in the UK within Black African communities: how common is it and how do we prevent it?

Dr Valerie Delpech

Public Health England

1800–1900

ViiV Healthcare Satellite Symposium (please see page 17 for further details)

1900–2000

Welcome Reception, Speeches in Auditorium 1

Chair: Dr Duncan Churchill

Royal Sussex County Hospital, Brighton

Dr David Asboe

Chelsea and Westminster Hospital, London

Caroline Lucas

Green Party

Drinks and canapés to be served in the Exhibition Hall on the ground floor following speeches in the Lecture Theatre



PROGRAMME

THURSDAY 23 APRIL 2015

0800–1830

Registration and exhibition open at The Brighton Centre

◀ All sessions will be held in Auditorium 1 unless otherwise stated ▶

0900–1000

MSD Ltd Satellite Symposium (please see page 17 for further details)

1000–1100

BHIVA Plenary Session 2: Managing and commissioning HIV services

Chairs: Dr David Asboe

Chelsea and Westminster Hospital, London

Professor Jane Anderson

*Homerton University Hospital NHS Foundation Trust***Commissioning HIV services in the NHS: which model is best?**

Dr James Palmer

*NHS England***Too many reviews; too much monitoring**

Professor Brian Angus

University of Oxford

1100–1130

Morning Coffee

1130–1300

Oral Research Presentations: Session 2**Antiretroviral Therapy**

Chairs: Dr Mas Chaponda

Royal Liverpool University Hospital

Dr Laura Waters

*Mortimer Market Centre, London***1130–1140 Abstract O7**

Enhanced immune reconstitution with initiation of ART at HIV-1 seroconversion (PHI)

*Dr Colette Smith, University College London***1140–1150 Abstract O8**

A Phase IV HIV PrEP study reveals limited ex vivo potency of oral Maraviroc against HIV-1

*Dr Juan Tiraboschi, Guys & St Thomas' NHS Foundation Trust, London***1150–1200 Abstract O9**

Cerebrospinal fluid markers in long-term atazanavir/ritonavir monotherapy

*Dr Francesca Ferretti, San Raffaele Scientific Institute, Milan, Italy***1200–1210 Abstract O10**

No difference in risk of virological failure between antiretroviral treatments using co-formulated versus individual drugs: Meta-analysis of 9 randomised trials in 2,568 patients

*Dr Andrew Hill, Chelsea & Westminster Hospital, London***1210–1220 Abstract O11**

The impact of boosted darunavir monotherapy on neurocognitive function and quality of life: Results from a prospective randomised study

*Dr Juan Tiraboschi, Guys & St Thomas' NHS Foundation Trust, London***1220–1230 Abstract O12**

Increasing uptake and adherence to ART initiated at a CD4>350: Data from the comprehensive national cohort of people living with diagnosed HIV infection

Dr Alison Brown, Public Health England

PROGRAMME

THURSDAY 23 APRIL 2015

1230–1240 Abstract O13

UK clinicians' approach to ART in primary HIV infection; comparison with the BHIVA guidelines
Dr Julie Fox, Guys' & St Thomas' NHS Foundation Trust, London

1240–1250 Abstract O14

Effects of long-standing antiretroviral therapy on semen HIV viral load
Dr Helen Iveson, Guy's & St Thomas' NHS Foundation Trust, London

1250–1300 Abstract O15

Trends in transmitted drug resistance to HIV-1 in the UK since 2010
Miss Anna Tostevin, MRC Clinical Trials Unit at UCL

1300–1500

Lunch, Workshops and Poster Presentations

1310–1355

BHIVA Lunchtime Workshop 3 Syndicate Room 1

Difficult pharmacology case presentations

Chair: Professor David Back
University of Liverpool

Pharmacological considerations in HIV co-infected with MDR TB

Dr Derek Cocker
Royal Liverpool University Hospital

A real QT

Dr Nadia Ahmed
Central and Northwest London NHS Foundation Trust

Sex, drugs and rhabdomyolysis

Dr Subathira Dakshina
Barts Health NHS Trust, London

1310–1355

BHIVA Lunchtime Workshop 4 Syndicate Room 2

BHIVA/UK-CAB Community Workshop: HIV-related stigma; influencing and changing attitudes

Chair: Ms Hosanna Bankhead
HIV Scotland

Dr Nina Pearson

Luton Clinical Commissioning Group

Mrs Fiona Wallis

Monkgate Health Centre, York

1355–1455

Bristol-Myers Squibb Pharmaceuticals Lunchtime Workshop Syndicate Room 3 (please see page 17 for further details)

1355–1455

ViiV Healthcare UK Lunchtime Workshop Syndicate Room 4 (please see page 17 for further details)

1500–1630

Oral Research Presentations: Session 3

Basic Science and Co-morbidities

Chairs: Professor Mark Bower

Chelsea and Westminster Hospital NHS Foundation Trust

Dr David Chadwick

James Cook University Hospital, Middlesbrough

1500–1510 Abstract O16

Early antiretroviral therapy reduces HIV-1 DNA following perinatal HIV-1 infection
Dr Caroline Foster, Imperial College Healthcare NHS Trust, London

PROGRAMME

THURSDAY 23 APRIL 2015

1510–1520 Abstract O17

Microbial translocation is associated with neuroinflammation in HIV subjects on ART
Dr Jaime Vera, Imperial College London

1520–1530 Abstract O18

CSF:plasma HIV-1 RNA discordance $>0.5\log_{10}$ is associated with raised inflammatory mediator profiles in CSF
Dr Benedict Michael, University of Liverpool

1530–1540 Abstract O19

Impact of rectal gonorrhoea and chlamydia on HIV viral load and inflammatory markers in the rectum; potential significance for onward transmission
Dr Olubanke Davies, Guy's & St Thomas' NHS Foundation Trust, London

1540–1550 Abstract O20

Treatment for hepatitis C infection in the UK Collaborative HIV Cohort (UK CHIC) study
Ms Alicia Thornton, University College London

1550–1600 Abstract O21

The exclusion of people living with HIV (PLWH) from clinical trials in lymphoma: prejudice or justified?
Dr Serena Venturelli, Chelsea & Westminster Hospital, London

1600–1610 Abstract O22

Initiation of anti-retrovirals in HIV/HCV-coinfected MSM: Are we too late?
Miss Sophie Jose, University College London

1610–1620 Abstract O23

Risk factors for acute allograft rejection in HIV-positive kidney transplant recipients
Miss Esther Gathogo, King's College London

1620–1630 Abstract O24

No association between vitamin D deficiency and parathyroid hormone, bone density and bone turnover in a large cohort of HIV-infected men on tenofovir
Dr Amanda Samarawickrama, Brighton and Sussex Medical School

1630–1700

Afternoon Tea

1700–1730

BHIVA Audit Session

Chair: Dr Andrew Freedman
Cardiff University School of Medicine

Audit of Management of Pregnancy in HIV

Dr Sonia Raffe
Royal Sussex County Hospital, Brighton

1730–1830

BHIVA Plenary Session 3: Clinical management

Chairs: Professor Caroline Sabin
University College London
Dr Ann Sullivan
Chelsea and Westminster Hospital, London

Update on the management of opportunistic infections

Dr Sanjay Bhagani
Royal Free Hospital, London

Vasculitis and HIV

Professor Priscilla Hsue
University of California, San Francisco, USA

1945–0030

Drinks reception and Gala Dinner (please see page 22 for further details)
The Grand Brighton Hotel

PROGRAMME

FRIDAY 24 APRIL 2015

0800–1430

Registration and exhibition open at The Brighton Centre

◀ All sessions will be held in Auditorium 1 unless otherwise stated ▶

0900–0930

BHIVA Invited Lecture 3

Chair: Dr Ed Wilkins

*North Manchester General Hospital***Ebola**

Dr Jake Dunning

University of Oxford

0930–1000

BHIVA Invited Lecture 4

Chair: Dr Carol Emerson

*The Royal Hospitals, Belfast***The latest in STI diagnostics**

Dr Suneeta Soni

Brighton and Sussex University Hospitals NHS Trust

1000–1030

BHIVA Keynote Lecture

Chair: Professor Brian Angus

*University of Oxford***What is the future of integrase inhibitors?**

Professor Martin Fisher

Brighton and Sussex Medical School

1030–1100

Morning Coffee

1100–1200

Oral Research Presentations: Session 4**Children and pregnancy**

Chairs: Dr Tristan Barber

Chelsea and Westminster Hospital, London

Dr Gillian Dean

*Brighton and Sussex University Hospitals NHS Trust***1100–1110 Abstract O25**

Neurocognitive function in perinatally HIV-infected young people and HIV-negative siblings in England

*Dr Ali Judd, MRC Clinical Trials Unit at University College London***1110–1120 Abstract O26**

To determine the prevalence of HIV seroreversion across 5 collaborating paediatric HIV centres in the UK

*Miss Amie Patel, Brighton and Sussex Medical School***1120–1130 Abstract O27**

Antiretroviral drug resistance in pregnant women living with HIV in England & Wales: Preliminary results from the matching of three national HIV surveillance databases

*Dr Laura Byrne, UCL Institute of Child Health***1130–1140 Abstract O28**

Teachers' awareness of HIV and the needs of children affected by HIV

*Dr Steven Welch, Birmingham Heartlands Hospital***1140–1150 Abstract O29**

Genital tract infections in HIV-infected pregnant women in south west London

Dr Aseel Hegazi, St George's University Hospital, London

PROGRAMME

FRIDAY 24 APRIL 2015

1150–1200 Abstract O30

Kids to adults: Tracking perinatally infected youth as they transition to adult care – the UK experience

Dr Intira Jeannie Collins, MRC Clinical Trials Unit at University College London

1200–1230

Oral Poster Presentations

Chairs: Dr Adrian Palfreeman

Leicester Royal Infirmary

Dr Laura Waters

Mortimer Market Centre, London

1230–1430

Lunch, Workshops and Poster Presentations

1240–1325

BHIVA Lunchtime Workshop 5 Syndicate Room 1

Pregnancy and breastfeeding case presentations

Chairs: Dr Annemiek de Ruiter

St Thomas' Hospital, London

Dr Yvonne Gilleece

Royal Sussex County Hospital, Brighton

It ain't gonna be easy

Dr Nurul Fadzillah

Countess of Chester Hospital NHS Trust

Elite control in pregnancy

Dr Alex Stockdale

Royal Liverpool University Hospital

Pharmacology never lies - what to do when nothing adds up!

Ms Chinyere Okoli

North Middlesex University Hospital NHS Trust, London

1240–1325

BHIVA Lunchtime Workshop 6 Syndicate Room 2

Chair: Professor Margaret Johnson

Royal Free Hospital, London

Clinical research: How to get involved and effective use of the Clinical Research Network

Dr David Chadwick

James Cook University Hospital, Middlesbrough

Dr Ann Sullivan

Chelsea and Westminster Hospital, London

1325–1425

FHIVA Lunchtime Workshop

Chair: Dr Steven Welch

Birmingham Heartlands Hospital

Role of the MDT in maintaining partner engagement with clinics after transition from paediatric to adult services

Dr Caroline Foster

Imperial College Healthcare NHS Trust, London

Dr Sarah Fidler

Imperial College Healthcare NHS Trust, London

Sara Ayres

Imperial College Healthcare NHS Trust, London

PROGRAMME

FRIDAY 24 APRIL 2015

1430–1445

BHIVA Prizes and Awards Ceremony

Chair: Dr David Asboe

Chelsea and Westminster Hospital, London

Dr Adrian Palfreeman

University Hospitals of Leicester NHS Trust

1445–1515

BHIVA Invited Lecture 5

Chair: Dr Annemiek de Ruiter

Guy's & St Thomas' NHS Foundation Trust

HIV and vulnerable populations: transgender medicine

Dr Anita Radix

Callen-Lorde Community Health Center, New York, USA

1515–1615

BHIVA Plenary Session 4: HIV and death

Chair: Dr Melinda Tenant-Flowers

King's College Hospital NHS Foundation Trust

Dr Ian Williams

Mortimer Market Centre, London

What can we learn from looking at HIV-related deaths in the cART era?

How is death in HIV-positive patients currently managed?

How can we better obtain post mortem tissue diagnoses in critical cases?

Miss Veronica Hamilton-Deeley

HM Coroner for Brighton & Hove

Professor Sebastian Lucas

King's College London

Professor Rob Miller

University College London Medical School

Dr Christopher Wood

North Middlesex University Hospital, London

1615

Close by the Chair of the British HIV Association

Dr David Asboe

Chelsea and Westminster Hospital, London



Patients Come First

Rapid, On-demand Testing for Better Patient Management

At Cepheid, improving the patient experience is our first priority. We are committed to delivering the most innovative and comprehensive virology products for the detection of HIV, Hepatitis C and Hepatitis B. We are focused on providing rapid and actionable results that improve patient outcomes and reduce complications in these most vulnerable populations.



Xpert® HIV-1 Viral Load*
Xpert® HIV-1 Qual^
Xpert® HCV Viral Load*
Xpert® HBV Viral Load#

Cepheid powers same-day results in more than 8,000 locations worldwide.
Learn more at cepheidinternational.com.

* CE-IVD. For in vitro diagnostic use. ^ Pending CE-IVD. # Not available for diagnostic use. Projected release 2016/2017 ex-US.



Cepheid®
A better way.

SATELLITE SYMPOSIA AND SPONSORS' LUNCHTIME WORKSHOPS

WEDNESDAY 22 APRIL 2015

*All Satellite Symposia will be held in Auditorium 1 and
Sponsors' workshops will be held in Syndicate Rooms 3 and 4*

1000–1100

Gilead Sciences Satellite Symposium

Differentiating options in a world of choice

Chair: Professor Simon Barton

Chelsea and Westminster Hospital, London

Dr Mas Chaponda

Royal Liverpool University Hospital

Professor Martin Fisher

Brighton and Sussex Medical School

Mrs Linda Panton

NHS Lothian, Edinburgh

Dr Anton Pozniak

Chelsea and Westminster Hospital, London

Our panel will debate on:

Is there a gold standard in HIV treatment?

Do stable PLWHIV need to be managed by a secondary care team?

Does NRTI choice matter?

1120–1220

Janssen Satellite Symposium

Making a connection: clinical cases

Chair: Dr Chloe Orkin

Barts Health NHS Trust, London

Dr Marta Boffito

Chelsea and Westminster Hospital, London

Dr Julie Fox

St Thomas' Hospital, London

Dr Peter Tate MBE

1355–1455

Gilead Sciences Lunchtime Workshop Syndicate Room 3

Cardiovascular disease and HIV: two diseases, one patient

Best practice sharing from joint clinics

Chair: Dr Duncan Churchill

Royal Sussex County Hospital, Brighton

Dr James Cockburn

Royal Sussex County Hospital, Brighton

Dr Roby Rakhit

Royal Free London NHS Foundation Trust

SATELLITE SYMPOSIA AND SPONSORS' LUNCHTIME WORKSHOPS

WEDNESDAY 22 APRIL 2015

1355–1455

Janssen Lunchtime Workshop Syndicate Room 4

It's a balancing act: but what is best for the patient?

Chair: Professor Anna Maria Geretti
University of Liverpool

Dr Yvonne Gilleece
Royal Sussex County Hospital, Brighton

Dr Ed Wilkins
North Manchester General Hospital

1800–1900

ViiV Healthcare UK Satellite Symposium

Perspectives in Practice: A Tale of Two Clinics

Chair: Dr Laura Waters
Mortimer Market Centre, London

Dr Daniel Richardson
Royal Sussex County Hospital, Brighton

Dr Gary Whitlock
Dean Street Clinic, London

Dr Andrew Ustianowski
North Manchester General Hospital

THURSDAY 23 APRIL 2015

0900–1000

MSD Ltd Satellite Symposium

Future-proofing ARV treatment: Sex, drugs and a life more ordinary...

Chair: Professor Jane Anderson
Homerton University Hospital, London

David Stuart
Dean Street Clinic, London

Professor David Back
University of Liverpool

Dr Mark Nelson
Chelsea and Westminster Hospital, London

1355–1455

Bristol-Myers Squibb Pharmaceuticals Lunchtime Workshop Syndicate Room 3

**Educating physicians and empowering women living with HIV:
an update from the SHE programme**

Chair: Professor Margaret Johnson
Royal Free Hospital, London

Silvia Petretti
Positively UK

Dr Carol Emerson
Royal Hospitals, Belfast

1355–1455


ViiV Healthcare UK Lunchtime Workshop Syndicate Room 4

Current issues affecting People Living with HIV (PLWHIV)

Five people with HIV will be speaking as part of this workshop

EXHIBITION FLOOR PLAN AND EXHIBITORS

The Brighton Centre



EXHIBITORS

- | | |
|---|--|
| 1 BASELINE | 17 Public Health England |
| 2 African Health Policy Network/
African Eye Trust | 18 Cepheid |
| 3 6PM | 19 Positively UK |
| 4 MSD Ltd | 20 Halve It |
| 5 National AIDS Trust | 21 NAM |
| 6 Merz Pharma UK Ltd | 22 The Sophia Forum |
| 7 Bristol-Myers Squibb Pharmaceuticals Ltd | 23 ViiV Healthcare UK Ltd |
| 8 HIV i-Base/UK Community Advisory Board | 24 AbbVie Ltd |
| 9 Blithe Computer Systems | 25 The Resource Alliance |
| 10 Janssen | 26 HIV Pharmacy Association (HIVPA) |
| 11 Janssen HCV | 27 Children's HIV Association (CHIVA) |
| 12 Gilead Sciences Ltd | 28 National HIV Nurses Association (NHVNA) |
| 13 Mildmay Mission Hospital | 29 Dietitians working in HIV/AIDS (DHIVA) /
Rehabilitation in HIV Association (RHIVA) |
| 14 Terrence Higgins Trust | 30 The Sussex Beacon |
| 15 Alere | 31 Gilead Sciences HCV |
| 16 Hologic | |

CONFERENCE INFORMATION


The Brighton Centre

King's Road · Brighton · East Sussex · BN1 2GR
Telephone: +44 (0)1273 292643 · www.brightoncentre.co.uk

Registration procedure

Registration includes access to all scientific sessions, including satellite symposia, the exhibition area, refreshments and lunch for the days specified in your registration acknowledgement correspondence.

Delegate badges

Badges must be worn at all times to gain access to the lecture theatre, catering and exhibition areas. The delegate lanyards have been sponsored by Gilead Sciences  GILEAD

Accompanying persons *Pre-booked and paid only*

Accompanying persons' fees include attendance at the Welcome Reception Civic Reception and Gala Dinner. Each event is individually priced. These tickets must have been requested and paid for in advance of the conference. Please note that these fees do not cover attendance at the scientific sessions, exhibition or catering areas of the conference.

BHIVA Lunchtime workshops

Places are limited and will be restricted to 80 delegates per workshop. Places at each workshop will be available onsite, on a first-come, first-served basis, at the door of the lunchtime workshop. Doors will open 15 minutes prior to the start of each workshop. Each workshop will begin promptly and lunch packs will be provided for delegates attending these sessions, where indicated.

BHIVA New Consultants Forum

The BHIVA New Consultants Forum will bring together new UK consultants (first 5 years of substantive consultant post, to include those in early locum post and/or those within 6 months of CCT) to discuss topics of mutual interest, to raise issues of concern and to provide feedback on these matters to the BHIVA Executive Committee. The Forum will run from 1730–2000 on Tuesday 21 April 2015. Those delegates attending sessions can register for a dinner to be held following the BHIVA New Consultants Forum from 2000. The New Consultants Forum will comprise of four forums, each devoted to a specific theme or topic. Places are limited and in principle have been made available on a first-come, first-served basis.

Continuing Professional Development (CPD)

Medical staff in career grade posts who are enrolled with one of the Royal Medical Colleges for Continuing Professional Development will be entitled to receive CPD credits at the rate of one CPD credit per conference hour (exclusive of travel, refreshments, pharmaceutical-supported sessions and social events). The unique reference code for the conference is 93270. The entire conference has been allocated 18 CPD credits. Please be advised that the attendance list of the conference will be forwarded to the Royal College of Physicians upon request.

Social events

There are two social events: a Welcome Reception (Wednesday) to be held at the Brighton Centre and a Gala Dinner (Thursday) to be held at The Grand Brighton Hotel. You will require a ticket to gain entry to the Gala Dinner. Please refer to page 22 of this programme for full details of the social events. If you have reserved a ticket but find that you cannot attend, please let the Conference Organiser know as soon as possible and return your ticket to the Registration Desk at your earliest convenience.

Poster presentations

All poster boards will be numbered and poster presenters should use the board displaying the number allocated to their poster. All poster presenters should be available by their poster for the final 30 minutes of the Wednesday and Thursday lunchtime sessions for potential discussion with delegates and poster judges. The poster judges will review the posters and subsequently select 15 posters to be highly commended, out of which six will be presented as part of the Oral Research Poster Presentations session at 1200–1230 on Friday 24 April. Poster presenters are required to prepare a few slides prior to the conference to highlight the main points of their poster. We would encourage all poster presenters to check the Registration notice board at 1700 on Thursday 23 April to see whether they have been selected. The BHIVA Ian Williams Best Poster prize will be awarded at the Prizes and Awards Ceremony on Friday 24 April at 1430–1445.

CONFERENCE INFORMATION

Oral research presentations

Oral research presenters are reminded to ensure they bring their oral research presentation slides to the conference in addition to sending them to the Conference Organisers in advance. Any slides must be passed to the audio-visual technicians in the Speakers' Preview Room located in 2Bar on the first floor in good time for their session (minimum 3 hours in advance). Oral research presenters may make use of the Speakers' Preview Room to review their slides prior to presentation. The BHIVA Margaret Johnson Best Oral Presentation prize will be awarded at the Prizes and Awards Ceremony on Friday 24 April at 1430–1445.

Accommodation

Please note that the registration fee does not include accommodation. If you have not already arranged accommodation you can do so by referring to the conference website for further details. It is very important to book accommodation early as rates will increase significantly nearer the time of conference.

WiFi

Free WiFi access will be available at the conference centre.

Cloakroom

A manned cloakroom is available onsite on the ground level at the Brighton centre. All belongings are left at the owner's risk. The British HIV Association do not accept responsibility for the loss of, or damage to, delegates' personal property stored in the cloakroom area.

Exhibition

The exhibition represents an integral element of the conference, providing participants with an excellent platform for networking as well as an opportunity to gain further insight into cutting-edge technology, the latest healthcare solutions, and services within the field of HIV and GU medicine. Entrance to the exhibition hall is free for all registered delegates.

Filming and photography

Please note that all sessions held in the lecture theatre (Auditorium 1) will be filmed and uploaded to the BHIVA websites following the event. In addition, some still photography will take place at the conference. This will include general coverage of registration, exhibition and workshop areas, as well as conference social events. This material may be published in BHIVA publications or on the BHIVA website.



SCHOLARSHIPS AND AWARDS

The BHIVA Margaret Johnson Best Oral Research Presentation

This prize will be awarded to the presenter of the best oral research presentation during the conference. All oral research presentations will be judged by a BHIVA-appointed oral research judging panel, and to be eligible for this prize the presenter must be of junior grade (sub-consultant or equivalent). The prize will be presented at the Prizes and Awards Ceremony on Friday 24 April.

The BHIVA Ian Williams Best Poster Presentation

This prize will be awarded to the presenter of the best poster research presentation during the conference. Poster research presentations will be judged by a BHIVA-appointed poster research judging panel, and to be eligible for this prize the presenter must be of junior grade (sub-consultant or equivalent). The prize will be presented at the Prizes and Awards Ceremony on Friday 24 April.

The BHIVA Best Case Presentation

A prize will be awarded to the presenter of the best case presentation as part of the BHIVA Lunchtime Clinico-Pathological, Difficult Pharmacology, and Pregnancy and Breastfeeding Case Presentations Workshops. The prizes will be presented at the Prizes and Awards Ceremony on Friday 24 April.

Commended Oral Presentation

Up to three awards will be presented in recognition of the best oral research presentations during the conference. To be eligible for these prizes the presenter must be of junior grade (sub-consultant or equivalent). All oral presentations will be judged by a BHIVA-appointed oral research judging panel. The awards will be acknowledged during the Prizes and Awards Ceremony on Friday 24 April.

Commended Poster Presentations

Up to 15 awards will be presented in recognition of the best poster research presentations during the conference. Poster research presentations will be judged by a BHIVA-appointed poster research judging panel. The prizes will be awarded at the end of Thursday 23 April. The awards will be acknowledged during the Prizes and Awards Ceremony on Friday 24 April.

Mediscript Awards in collaboration with BHIVA

Two prizes will be awarded for the best oral or poster research presentation during the conference in the field of social sciences and community-based work. The awards will be presented at the Prizes and Awards Ceremony on Friday 24 April.

BHIVA Science Scholarships

Science Scholarships have been awarded to 10 researchers and scientists whose abstracts have been accepted for presentation. All registration fees, a contribution towards travel expenses and accommodation costs are paid by BHIVA to successful candidates.

BHIVA Registration Scholarships

Registration Scholarships have been awarded to 10 delegates who are either healthcare professionals who are retired, not working, or employed in a part-time or equivalent capacity, or who are students involved in full-time undergraduate or postgraduate work. The scholarship covers the conference registration fee.

BHIVA Community Registration Support

BHIVA has supported the registrations of approximately 40 delegates from community organisations in order to assist them with attending the conference.

BHIVA Community Scholarships

Community Scholarships have been awarded to 11 UK-based community registrants to assist them to attend the conference. For those applicants selected, all registration fees and a contribution towards expenses and accommodation costs are paid by BHIVA.

SOCIAL EVENTS

Welcome Reception

The Brighton Centre

Wednesday 22 April 2015: 1900–2000

Through the dedication of the Brighton Centre team and the iconic location of the building, right on the seafront, the Brighton Centre continues to generate millions for the local economy, winning conferences, entertainments, and events business from all over the world. With the continuous investment into the fabric of the building by Brighton & Hove City Council the venue continues to go from strength to strength.

Top attractions to enjoy whilst in Brighton include the world famous Royal Pavilion, summer palace of King George IV, Brighton Marina with its boardwalk of bars and restaurants, all enjoying spectacular sea views, and the exciting Brighton Pier, one of England's top free tourist attractions. With five shopping districts including the famous and historic Lanes and North Laine, over 400 restaurants and the sparkling nightlife, the only commodity in short supply will be time.

We are honoured that Caroline Lucas from the Green Party has kindly agreed to speak and officially welcome delegates to the city.

The Welcome Reception will begin with a few short speeches in the lecture theatre (Auditorium 1) followed by an opportunity for delegates to network in the exhibition area whilst enjoying a drink and some light refreshments.



Programme of events

- 1900–1915 Speeches
- 1915–2000 Drinks and canapés
- 2000 Close

Gala Dinner

Ticket required

Dress code: Gentlemen are requested to wear jacket and tie

The Grand Brighton Hotel

Thursday 23 April 2015: 1945–0030

The Grand Brighton Hotel is an iconic building which stands proudly on the East Sussex city's seafront. The traditional Victorian hotel is one of the most memorable and familiar of the many hotels lining Brighton's sea-facing King's Road. Grand by name, grand by nature; there is an air of elegance and longevity that graces this popular grande dame. The impressive hotel boasts fantastic views from its sea-facing bedrooms and its restaurant. A multi-million pound refurbishment was completed in July 2013 which makes it the place to stay on Brighton's seafront.

We are honoured that The Right Worshipful the Mayor of The City of Brighton and Hove, Councillor Brian Fitch, has kindly agreed to speak as part of the Gala Dinner.

The Gala Dinner will commence with a drinks reception followed by dinner at The Grand Brighton Hotel. After some short speeches, entertainment will include a magician, drag act and DJ Greg Marshall.



Programme of events

- Drinks Reception
- Gala Dinner
- Speeches
- Music and dancing
- Entertainment

HIV Medicine

The Official Journal of the
British HIV Association (BHIVA)

Deutsche AIDS-Gesellschaft (DAIG)
and the European AIDS Clinical Society (EACS)

Edited by
Brian Gazzard and Jens Lundgren

Impact Factor 2013: 3.454

ISI Ranking 2013: 20/72 (Infectious Diseases)

Online ISSN: 1468-1293

HIV Medicine aims to provide an alternative outlet for publication of international research papers in the field of HIV Medicine, embracing clinical, pharmacological, epidemiological, ethical, preclinical and *in vitro* studies. The journal also commissions reviews and other feature articles.

HIV Medicine focuses on evidence-based medicine as the mainstay of successful management of HIV and AIDS. It is aimed particularly at researchers and clinicians with responsibility for treating HIV seropositive patients.



For more information, and
to view FREE content visit:
<http://bit.ly/1i8hHWq>



Follow us on twitter @WB_InfDisease

BIOGRAPHIES

Brian Angus is Associate Professor and Reader in Infectious Diseases in the Nuffield Department of Medicine, Oxford University and a Senior Clinical Scientist with the MRC CTU. He is also Director of Oxford University's Centre for Tropical Medicine and Global Health and NHS Clinical Lead for ID in Oxford University Hospitals NHS Trust. Brian is chairing the BHIVA guidelines committee on monitoring patients living with HIV.

David Asboe is Clinical Director of HIV Medicine and Sexual Health at Chelsea and Westminster Hospital, London. He studied medicine at Otago University, New Zealand and completed specialist training at St Thomas' Hospital, London. David is the Convener of the Diploma in HIV Medicine, and is a Trustee on the Executive Committee of the British HIV Association. He was elected as BHIVA Chair in 2013.

Claire Ashley is a Senior Industrial Relations Officer working in the BMA's North West Centre providing industrial relations support to LNCs and members throughout Merseyside and Lancashire. She also manages a team of 15 advisory staff across the North of England. Claire has worked for the BMA since 1993 in a variety of roles in Regional Services, in the North West, London and the South East and Oxfordshire. She is a member of the Institute of Personnel and Development and has a Master's Degree in Industrial Relations and Labour Law.

David Back is a Professor of Pharmacology at the University of Liverpool and has worked in the area of pharmacokinetics and drug-drug interactions for more than 35 years. He established the Liverpool HIV Pharmacology Group (LHPG) in 1987 and subsequently the Liverpool group has been at the forefront of pharmacological research of anti-infective drugs, specifically for HIV and HCV. Currently there are numerous ongoing pharmacokinetic, pharmacogenetic and molecular-based studies involving local, national and international collaborations. David has authored ~400 publications. He is a former Editor-in-chief of the British Journal of Clinical Pharmacology and is on the Editorial Board of numerous journals. He has established several key resources for healthcare professionals including www.hiv-druginteractions.org and www.hep-druginteractions.org. In 2007 he was awarded the Lilly Prize from the British Pharmacological Society for outstanding contribution to Clinical Pharmacology.

Sanjay Bhagani is an Infectious Diseases/HIV Medicine and General (internal) Medicine Consultant at the Royal Free Hospital and an honorary Senior Lecturer at UCL. He is the current Chair of the BHIVA Hepatitis Committee and the International Partnerships Group. Sanjay has a particular interest in managing complex opportunistic infections in the context of HIV-associated immune suppression.

David Chadwick is an ID Physician in Middlesbrough who has worked in HIV for 20 years, with research interests in HIV and viral hepatitis co-infection in Africa, and HIV testing in the UK. David has contributed to BHIVA through the Immunisation guidelines and HIV-2 committees, CROI feedback sessions, the UK CHIC Executive Committee and Diploma in HIV Medicine question setting.

Duncan Churchill has been a Consultant in GU/HIV Medicine at the Royal Sussex County Hospital in Brighton since 1999. He trained at Oxford University and at The Middlesex Hospital Medical School. Before taking up his current appointment he was a Lecturer and Honorary Senior Registrar at Imperial College School of Medicine at St Mary's, and also worked as HIV Registrar at The Middlesex Hospital. Duncan has been a member of the Executive Committee of the British HIV Association from 1996–2004 and 2009 to date, and has been on the BHIVA Guidelines Writing Group since inception. He was Vice Chair of the 2012 BHIVA Treatment Guidelines Writing Group, and became Chair in 2013; he also chairs the Guidelines Subcommittee, and was elected Honorary Treasurer of BHIVA in 2014.

Annemiek De Ruiter is a Consultant Physician in HIV/GUM at St Thomas' Hospital, London and has managed HIV-positive patients for over 20 years, specialising in the management of pregnant women with HIV. She has published extensively, formed local and national networks, collaborated widely, advised at a national level, lectured nationally and internationally, and led the development of the BHIVA 2012 and 2014 Pregnancy guidelines. Annemiek is the BHIVA Honorary secretary and sits on the BHIVA Conferences and Guidelines Subcommittees.

Valerie Delpech is a Medical Epidemiologist based at Public Health England and leads a team of scientists and data managers to monitor the HIV epidemic and the quality of care people living with HIV receive in the UK. Her research interests focus on better understanding the epidemiology of HIV and STIs, and public health interventions to prevent these infections among vulnerable populations. Valerie serves on a number of national and international committees in relation to HIV public health monitoring, prevention and policy development and is an executive trustee for the National AIDS Trust.

Jake Dunning is a Consultant in Infectious Diseases and a Senior Clinical Researcher at the Centre for Tropical Medicine and Global Health, University of Oxford. A graduate of Imperial College School of Medicine, he trained in HIV medicine at Chelsea and Westminster Hospital and St Mary's Hospital, London. Jake's research interests include emerging infections and respiratory viruses, particularly mechanisms of pathogenesis and clinical trials. His PhD at Imperial focused on transcriptomic and cytokine profiles in patients with severe pandemic influenza. He also works with WHO and ISARIC on clinical management and research aspects of MERS coronavirus and avian influenza infection. Since October 2014, Jake has been based in West Africa, running clinical trials of potential treatments for Ebola virus disease.

Martin Fisher is currently Chair of HIV Medicine and has been a Consultant Physician in Brighton since 1995. He has a large cohort of HIV outpatients, and runs joint clinics for patients with hepatitis C co-infection and for patients with multiple co-morbidities. Martin's research interests include HIV testing, transmission, primary infection, and ageing. He has been a co-author of BHIVA guidelines on antiretroviral therapy, hepatitis co-infection, HIV testing, treatment as prevention, and pre-exposure and post-exposure prophylaxis.

Caroline Foster is a Consultant in Adolescent Infectious Diseases and HIV at Imperial College Healthcare NHS Trust. Caroline's research interests include transitional care and the long-term outcomes for adults with perinatally acquired HIV infection.

BIOGRAPHIES

Julie Fox is an HIV Consultant at Guy's and St Thomas' NHS Trust and runs the HIV Clinical Trials Unit. Her research interests include acute HIV, HIV transmission/prevention, gut immunology and HIV cure. Julie is part of the UK CHERUB research group and collaborates nationally and internationally.

Stuart Gibson has worked across the UK, USA and Canada for nearly 20 years. In addition to providing psychological therapy, he has also taught, trained and published research in HIV, sexual health and sexual diversity in a variety of settings. Stuart recently served as the Chair of the Faculty for HIV & Sexual Health with the British Psychological Society, where he shared a leadership role in setting national standards for providing psychological support to adults living with HIV. He is now a member of the MSM Special Interest Group with BASHH.

Veronica Hamilton-Deeley took a Law degree at Southampton University and then qualified as a Solicitor. She worked in private practice in Brighton, specialising in employment law and medical claims. Veronica became an Assistant Coroner and part time Tribunal Judge in the late 1980s. In 1997 she was appointed to be the Brighton and Hove Coroner. She has a particular interest in the needs of the population of Brighton and Hove. She continues to be involved in training on coronial matters including the role of the coroner.

Priscilla Hsue earned her MD in 1996 from the University of California, San Francisco, where she is now Professor of Medicine, having been on faculty in the department since 2002. Her research interest is in the pathogenesis, clinical manifestations, and treatment of cardiovascular disease and inflammation in HIV-infected patients. As Co-Director of the Center for Vascular Excellence at UCSF, Priscilla has extensive experience in ultrasound imaging including assessment of carotid artery intima-media thickness and assessment of endothelial function using flow-mediated vasodilation of the brachial artery, and has used both of these techniques to study HIV-infected individuals with the purpose of ascertaining the pathophysiology of HIV-related cardiovascular disease and the role of inflammation in this disease process. She is widely published in the area of HIV-related cardiovascular disease and inflammation. She runs the HIV Cardiology Clinic at San Francisco General Hospital and is one of the few cardiologists internationally with clinical as well as research expertise in this area. She is Principal Investigator of a multicentre clinical trial to evaluate the cardiovascular impact of low dose methotrexate in HIV.

Sebastian Lucas has spent three decades as a Histopathologist, studying the clinical pathology of HIV/AIDS in UK and Africa. Sebastian's main concerns have been making best use of biopsy and autopsy material to further diagnostics, better patient management, and in research.

Alexander Margetts has worked as a Clinical Psychologist in HIV and sexual health at Chelsea and Westminster Hospital for the past 6 years, and is also currently the Chair of the British Psychological Society (BPS) Faculty for HIV & Sexual Health. Therapeutically he works predominately from a Cognitive Behavioural Therapy (CBT) background, and also leads on Neuropsychology for the service. Alongside clinical work, Alexander's role includes service development, supervision, teaching, training and consultation.

Sheena McCormack has been coordinating HIV prevention trials since 1994. From the outset she worked on HIV vaccine trials, all Phase I/II, in Europe and Africa. Since 1998 she has been involved in microbicide trials and is co-PI of the Microbicides Development Programme (MDP), a multi-disciplinary public-private partnership. Sheena was Chief Investigator of the Phase III clinical trial that enrolled 9,385 women through six research centres in Southern Africa and reported in 2009. She is a partner in several vaccine and microbicide networks and working with colleagues in the UK to determine the role of PrEP in the national strategy leading the PROUD pilot study.

Rob Miller is Reader in Clinical Infection at University College London (UCL), Honorary Professor at the London School of Hygiene and Tropical Medicine, and Honorary Consultant at Camden Provider Services NHS Trust and UCL Hospitals NHS Trust. Rob's research interests relate to the effects of HIV on innate immunity and the respiratory complications of HIV infection, particularly *Pneumocystis jirovecii* pneumonia and tuberculosis.

Colm O'Mahony was a consultant in Sexual Health and HIV at The Countess of Chester Hospital for 25 years until 01.02.15. The farce started when Sexual Health services were transferred to local councils. The farce continued as the service was tendered out and an NHS Trust some 50 miles away won the bid; based on modular buildings moved every 6 months! This disintegrated the SH and HIV team. This led to my work/life balance shifting more to work and, despite excellent skill in mindfulness techniques, has left me unbalanced. However, the ferocious campaign I mounted both in the press and political circles has been professionally rewarding, even if dismally unsuccessful. I have learnt a lot and hope to convey this in my work/life balance talk. Perhaps I should have called it, "How to have a life and maintain a professional work ethic in the face of ineptitude and incompetence".

Chloe Orkin is a Consultant and Honorary Reader in HIV Medicine at the Royal London Hospital and runs an HIV and HIV/Hepatitis C research unit. She has led several HIV testing initiatives in East London. Chloe is currently Chair of the BHIVA Conferences Subcommittee. She has contributed to four BHIVA Guidelines: Treatment, Hepatitis, Malignancy and Routine Monitoring. Chloe is an External Examiner to the Diploma in HIV Medicine.

James Palmer qualified in Medicine at The London Hospital Medical College in 1985, and trained in Neurosurgery in Southampton and Glasgow. He moved to Plymouth from a clinical academic position at the National Hospital for Neurology and Neurosurgery, Queen Square in 1999. James led a transformation in the Peninsula Neuroscience Services including the establishment of the South West Stereotactic Radiosurgery Service. In January 2005, he became Assistant Medical Director (Operations) at Plymouth Hospitals NHS Trust and onwards to Joint Medical Director. He moved from provider medical leadership to commissioning in 2009 as Medical Director South West Specialised Commissioning Group. After working as clinical lead in the transition period in April 2013, James was appointed Clinical Director Specialised Services in the Medical Directorate within NHS England. He has developed a broad clinical leadership model with the NHS England national Clinical Reference Groups and leads the strategic planning of the direct commissioning of specialised services whilst continuing his role as Consultant Neurosurgeon at Plymouth Hospitals NHS Trust.

BIOGRAPHIES

Nina Pearson has been a GP for 28 years, working now as a part time partner in Lea Vale Medical Group in Luton. This is a practice of 22,000 patients over three sites, with a diverse ethnic and cultural population mix. Luton has an HIV prevalence of 4.2/1000, with Lea Vale having the largest number of HIV-positive patients in the town. Nina has a special interest in Gynaecology and Sexual Health which is put to good use at practice level as well as local strategic level. For the last 2 years Nina has been Clinical Chair of the Luton CCG.

Andrew Phillips is Professor of Epidemiology at UCL and has worked in the HIV field for the past 25 years, on HIV observational cohorts (including the Royal Free Haemophilia Cohort, CASCADE, EuroSIDA, D:A:D, and COHERE/PLATO), randomized trials (including INSIGHT SMART and START trials) and simulation modelling (HIV Synthesis model). Work on observational studies began with describing the link between time updated CD4 count and risk of AIDS and other aspects of HIV natural history, including effects of age and viral load. As effective therapy became available Andrew moved on to examining effects of antiretroviral therapy in large clinical cohorts. Particular areas of interest have included virologic failure, drug resistance, adverse effects of ART, and the link between HIV and risk of non-AIDS diseases. He has latterly used individual-based simulation models of HIV transmission, progression and the effect of ART in an attempt to address public health questions not addressable in trials or analyses of observational studies, both in developed and developing country contexts. Much of his work involves close collaboration with Copenhagen HIV Programme (CHIP).

Anita Radix is the Director of Research and Education at the Callen-Lorde Community Health Center in New York, a centre that serves the lesbian, gay, bisexual and transgender communities. She qualified in the West Indies and completed postgraduate training in internal medicine and infectious diseases at the University of Connecticut. Anita holds faculty positions at NYU and Yale, and serves on the editorial board of the *International Journal of Transgenderism*. She has been involved in writing national and international guidelines for transgender health, as well as developing training modules in LGBT health for healthcare providers.

Sonia Raffae is a Specialty Registrar in HIV and GUM in Brighton. She completed her undergraduate degree at Newcastle University and later her MSc in Tropical Medicine and International Health at the London School of Hygiene and Tropical Medicine. Sonia was invited to be on the BHIVA Audit and Standards subcommittee to work on the 2013/14 audit of the management of HIV in pregnancy.

Caroline Sabin is Professor of Medical Statistics and Epidemiology at University College London (UCL) and is Director of the National Institutes for Health Research (NIHR) Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections, a partnership between UCL, Public Health England (PHE) and the London School of Hygiene and Tropical Medicine. Caroline has worked for many years on the analysis of large observational HIV databases with a particular interest in raising awareness of the biases inherent in these databases; she is the principal investigator on the UK CHIC Study, the principal statistician on the D:A:D Study, co-principal investigator on the POPPY Study, and has worked with many other research groups in the UK and elsewhere. time updated CD4 count and risk of AIDS and other aspects of HIV natural history, including effects of age and viral load. As effective therapy became available he moved on to examining effects of antiretroviral therapy in large clinical cohorts. Particular areas of interest have included virologic failure, drug resistance, adverse effects of ART, and the link between HIV and risk of non-AIDS diseases. He has latterly used individual-based simulation models of HIV transmission, progression and the effect of ART in an attempt to address public health questions not addressable in trials or analyses of observational studies, both in developed and developing country contexts. Much of his work involves close collaboration with Copenhagen HIV Programme (CHIP).

Gabriel Schembri graduated from the University of Malta as a Medical Doctor in 2001. He moved into dermato-venereology from general medicine in 2006, working with a number of UK-trained physicians and gaining valuable experience in both sexual health and dermatology. He subsequently moved to the UK and trained in genito-urinary medicine in Leicester. Gabriel is currently employed by the Central Manchester Foundation Trust as a Consultant in Genito-Mrinary Medicine, and where he is also the Research Lead. He is the PI in a number of commercial and non-commercial trials and he also runs a monthly joint HIV-renal clinic along with his renal colleagues.

Suneeta Soni has been a Consultant in Sexual Health and HIV in Brighton since 2010. Although her priorities are in clinical work and undergraduate teaching, she is active in research. She was PI of a study examining rectal chlamydia types in MSM using high-resolution genotyping methods and is currently CI of a study investigating the feasibility and cost-effectiveness of pooling genital and non-genital swabs in MSM using the BD ProbeTec™ CT/GC Qx Assay. Suneeta is also a member of the Bacterial Special Interest Group for BASHH.

Ann Sullivan trained in Australia and London, gaining an MD in HIV Immunology. She is a Consultant at Chelsea and Westminster Hospital. Her specific interests include expanding HIV testing, MSM sexual health and utilising technology to improve patient care and experience. Ann is the North West London CRN Specialty Lead for ID and microbiology.

Chris Wood is a Consultant in HIV Medicine at the North Middlesex University Hospital NHS Trust (NNUH) in North London. The NNUH has one of the largest HIV cohorts of any non-teaching hospital in the UK. He has been looking after HIV-positive individuals since 1988. Chris completed his specialist training at the Chelsea and Westminster and St Thomas' Hospitals. His main clinical interests are in the management of HIV-positive pregnant women and marginalised migrant communities and asylum seekers. He has contributed to the current BHIVA OI Treatment guidelines and to previous Antenatal HIV guidelines.

SPONSORS AND EXHIBITORS

BHIVA MAJOR SPONSORS 2015

AbbVie Ltd

Abbott House,
Vanwall Business Park
Maidenhead
Berkshire SL6 4XE



Bristol-Myers Squibb Pharmaceuticals Ltd

Uxbridge Business Park,
Sanderson Road
Middlesex UB8 1DH



Bristol-Myers Squibb

Gilead Sciences Ltd

280 High Holborn,
London
WC1V 7EE



GILEAD

Janssen

50–100 Holmers Farm Way,
High Wycombe
Buckinghamshire HP12 4DP



MSD Ltd

Hertford Road,
Hoddesdon
Hertfordshire EN11 9BU



MSD

ViiV Healthcare UK Ltd

Stockley Park West,
Uxbridge
Middlesex UB11 1BT



CONFERENCE EXHIBITORS

Pharmaceutical and Commercial

6PM Plc

Alere

Blithe Computer Systems

Cepheid

Gilead Sciences HCV

Hologic

Janssen HCV

Merz Pharma UK Ltd

Affiliated, Educational and Charitable

Children's HIV Association (CHIVA)

Dietitians Working in HIV/AIDS (DHIVA) /
Rehabilitation in HIV Association (RHIVA)

Halve It

HIV Pharmacy Association (HIVPA)

Mildmay Mission Hospital

National HIV Nurses Association (NHIVNA)

Public Health England

Community

African Health Policy Network (AHPN)

BASELINE

HIV i-Base/ UK Community Advisory Board (UK-CAB)

National AIDS Trust (NAT)

NAM

Positively UK

Terence Higgins Trust

The Resource Alliance

The Sophia Forum

The Sussex Beacon



innerstrength

The only single-pill regimen built with dolutegravir

The components of TRIUMEQ* form the first HIV regimen to have demonstrated statistically superior efficacy vs Atripla® in treatment-naïve patients at 48, 96 and 144 weeks^{1,2,3}

For further information visit www.dolutegravir.com.

*In studies supporting TRIUMEQ, DTG 50 mg + ABC 600 mg/3TC 300 mg were used. Bioequivalence has been demonstrated.⁴

Atripla® is not licensed for initial use in treatment-naïve patients.

Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B*5701 allele should be performed, please see prescribing information below for further information.

Triumeq®▼ dolutegravir 50mg/abacavir 600mg/lamivudine 300mg tablets
See Summary of Product Characteristics before prescribing.

Indication: HIV in over 12 years and ≥ 40 kg. Screen for HLA-B*5701 prior to use. Do not use if HLA-B*5701 positive. **Dose:** one tablet once daily with or without food. **Elderly:** Limited data in 65+ yrs. **Creatinine clearance** <50 ml/min or **moderate/severe hepatic impairment:** Not recommended. **Contraindications:** Hypersensitivity to any ingredient. Co-administration with dofetilide. **Warnings/precautions:** Both abacavir and dolutegravir are associated with risk of hypersensitivity reactions (HSR). Do not initiate in HLA-B*5701+ or previous suspected abacavir HSR. Stop Triumeq without delay if HSR suspected. Never reintroduce any dolutegravir- or abacavir-containing product after suspected HSR. Risks of lactic acidosis, lipodystrophy, immune reactivation syndrome, osteonecrosis. Monitor LFTs in Hepatitis B/C co-infection. Inconclusive data on relationship between abacavir and MI; minimise all modifiable CV risk factors (e.g. smoking, hypertension, hyperlipidaemia). Not recommended if dolutegravir required b.d. Use with cladribine, emtricitabine, enzyme inducers e.g. anticonvulsants, St John's Wort, not recommended. Use with etravirine requires boosted PI. Use with Mg/Al-containing antacids, calcium, multivitamins or iron requires dosage separation. Caution with ribavirin, metformin. **Pregnancy/lactation:** Not recommended. Avoid breast-feeding. **Side effects:** See SPC for details. Headache, insomnia, sleep/dream disorders, GI disturbance, fatigue, hypersensitivity, anorexia, depression, dizziness, somnolence, lethargy, malaise, cough, nasal symptoms, rash, pruritus, alopecia, arthralgia, muscle disorders, asthenia, fever, elevations of ALT, AST and CPK, blood dyscrasias, rhabdomyolysis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis.

Basic NHS costs: 30 tablets: £798.16 EU/1/14/940/001. MA holder: ViiV Healthcare UK Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS. Further information is available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT.

POM

Triumeq is a registered trademark of the ViiV Healthcare Group of Companies
Date of approval: November 2014. Zinc code: UK/TRIM/0037/14(2)

Adverse events should be reported. For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

Adverse events should be reported. For Ireland, adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971, medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Reference

1. Walmsley et al. N Engl J Med. 2013; 369: 1807-1818. 2. Walmsley et al. Abstract 543. 21st CROI; March 3-6, 2014; Boston, MA. 3. Pappa et al. ICAAC 2014; Washington, DC. H-647a. 4. TRIUMEQ Summary of Product Characteristics, Sept 2014.



TRIUMEQ is a registered trademark of the ViiV Healthcare group of companies.
Atripla is a registered trademark of Bristol-Myers Squibb & Gilead Sciences, LLC.
©2015 ViiV Healthcare group of companies All rights reserved.

Date of preparation: January 2015
UK/TRIM/0022/14(2)